American Society of Hematology Annual Meeting

Scemblix May Outperform Standard Treatments for Chronic Myeloid Leukemia

December 8th 2024, 11:47pm

Article

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

December 8th 2024, 11:25pm

Article

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.

Tecartus Shows Similar Efficacy Across Age Groups in Leukemia

December 8th 2024, 11:00pm

Article

Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Revuforj Continues to Elicit Meaningful Responses in Some With Acute Leukemia

December 8th 2024, 6:22pm

Article

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

D-VRd May Improve Minimal Residual Disease Responses in Multiple Myeloma

December 8th 2024, 5:36pm

Article

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.

Smoking May Be Linked With Genetic Mutations, Progression Risk in MDS

December 7th 2024, 7:28pm

Article

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

CAR-T Cell Therapy Shows EFS Benefit in Pediatric Leukemia Subset

December 7th 2024, 4:30pm

Article

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

Blincyto With Chemo May Improve Disease-Free Survival in Pediatric B-ALL

December 7th 2024, 3:04pm

Article

Pediatric patients with standard-risk B-ALL demonstrated significantly improved disease-free survival with Blincyto plus chemotherapy versus chemotherapy alone.

What is Cytoreduction in MPNs?

December 25th 2023, 10:00pm

Article

Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.

High Responses to Jaypirca in Relapsed CLL With BTK Mutations

December 20th 2023, 2:00pm

Article

Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.